Annual report pursuant to Section 13 and 15(d)

BALANCE SHEETS

v3.21.1
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 5,413 $ 5,223
Receivables 884 438
Inventory 328 563
Prepaid expenses and other current assets 522 534
Discontinued operations - current assets 181 1,550
Total current assets 7,328 8,308
Property and equipment, net 618 817
Operating lease right-of-use asset 141 397
Total Assets 8,087 9,522
Current liabilities:    
Accounts payable 1,253 815
Accrued clinical trials expenses 214 169
Other accrued liabilities 319 264
Operating lease liability, current 150 272
Current portion of long-term debt 327 0
Discontinued operations - current liabilities 1,960 2,080
Total current liabilities 4,223 3,600
Long-term debt, net of debt discount of $0 and $346 332 4,019
Warrant liability 0 320
Operating lease liability, non-current 0 150
Total liabilities 4,555 8,089
Commitments and contingencies (Note 5)
Stockholders' equity    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2020 and 2019. 0 0
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 7,139,068 and 1,912,627 shares issued and outstanding at December 31, 2020 and 2019, respectively. 7 2
Additional paid-in capital 370,804 350,468
Accumulated deficit (367,279) (349,037)
Total stockholders' equity 3,532 1,433
Total liabilities and stockholders' equity $ 8,087 $ 9,522